David R Coghill1, Sinead M Rhodes, Keith Matthews. 1. Section of Psychiatry and Behavioral Sciences, Division of Pathology and Neuroscience, University of Dundee, Ninewells Medical School, Dundee, United Kingdom. d.r.coghill@dundee.ac.uk
Abstract
BACKGROUND: The reported neuropsychological effects of methylphenidate (MPH) in attention-deficit/hyperactivity disorder (ADHD) are inconsistent. The assumed relationships between these neuropsychological effects and clinical efficacy have not been substantiated. We therefore investigated the effects of chronic MPH administration on neuropsychological functioning. METHODS: We conducted a 12-week, placebo-controlled, double-blinded, randomized, crossover trial (MPH .3 and .6 mg/kg/dose and placebo). Participants were 75 boys aged 7-15 years with ADHD. Neuropsychological performance was assessed with tests taken from the Cambridge Neuropsychological Test Automated Battery (CANTAB) battery and a GoNoGo task. RESULTS:Chronic MPH improved performance (p < .001) on aspects of the GoNoGo task (p < .02) and on three CANTAB tasks which together contributed to a "recognition memory" component identified through principal components analysis (delayed matching to sample [DMtS], pattern and spatial recognition). There were no effects on other, high or low "executive demand" tasks (p > .05). GoNoGo performance improvements were the only neuropsychopharmacological changes associated with clinical response. Poor performance on the DMtS task was the sole baseline neuropsychological predictor of clinical response. CONCLUSIONS: Chronic MPH predominantly enhanced neuropsychological functioning on "recognition memory" component tasks with modest "executive" demands. Neuropsychological measures offer only modest contributions to the prediction of clinical responses to MPH in ADHD.
RCT Entities:
BACKGROUND: The reported neuropsychological effects of methylphenidate (MPH) in attention-deficit/hyperactivity disorder (ADHD) are inconsistent. The assumed relationships between these neuropsychological effects and clinical efficacy have not been substantiated. We therefore investigated the effects of chronic MPH administration on neuropsychological functioning. METHODS: We conducted a 12-week, placebo-controlled, double-blinded, randomized, crossover trial (MPH .3 and .6 mg/kg/dose and placebo). Participants were 75 boys aged 7-15 years with ADHD. Neuropsychological performance was assessed with tests taken from the Cambridge Neuropsychological Test Automated Battery (CANTAB) battery and a GoNoGo task. RESULTS: Chronic MPH improved performance (p < .001) on aspects of the GoNoGo task (p < .02) and on three CANTAB tasks which together contributed to a "recognition memory" component identified through principal components analysis (delayed matching to sample [DMtS], pattern and spatial recognition). There were no effects on other, high or low "executive demand" tasks (p > .05). GoNoGo performance improvements were the only neuropsychopharmacological changes associated with clinical response. Poor performance on the DMtS task was the sole baseline neuropsychological predictor of clinical response. CONCLUSIONS: Chronic MPH predominantly enhanced neuropsychological functioning on "recognition memory" component tasks with modest "executive" demands. Neuropsychological measures offer only modest contributions to the prediction of clinical responses to MPH in ADHD.
Authors: Blythe A Corbett; Laura J Constantine; Robert Hendren; David Rocke; Sally Ozonoff Journal: Psychiatry Res Date: 2009-03-12 Impact factor: 3.222
Authors: Jesse S Rodriguez; Nicole R Zürcher; Thad Q Bartlett; Peter W Nathanielsz; Mark J Nijland Journal: J Neurosci Methods Date: 2011-01-27 Impact factor: 2.390
Authors: Hanna Kovshoff; May Vrijens; Margaret Thompson; Lucy Yardley; Paul Hodgkins; Edmund J S Sonuga-Barke; Marina Danckaerts Journal: Eur Child Adolesc Psychiatry Date: 2013-03-02 Impact factor: 4.785
Authors: Brian Daly; Mary C Kral; Ronald T Brown; David Elkin; Avi Madan-Swain; Monica Mitchell; Lori Crosby; David Dematteo; Angela Larosa; Sherron Jackson Journal: J Dev Behav Pediatr Date: 2012-04 Impact factor: 2.225